Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sendai virus vaccine
- Development stage
- Phase 1
- Lead developer
- St. Jude Children's Research Hospital
- Modality
- Live Vector Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
Sendai virus vaccine is an experimental live-attenuated, intranasally administered viral vaccine based on the murine parainfluenza virus type 1 (Sendai virus). It is being developed primarily as a Jennerian (xenotropic) live-virus vaccine for the prevention of human parainfluenza virus type 1 (hPIV-1) infection in children. The mechanism of action involves induction of both systemic and mucosal immune responses—specifically increasing serum and nasal IgG/IgA antibodies against hPIV-1—by mimicking natural infection without causing disease in humans. Preclinical studies have shown that it elicits strong protective immunity in animal models without significant adverse effects. Early-phase clinical trials in seropositive children and adults demonstrated that the intranasal administration was well tolerated with only mild transient side effects and no serious adverse events. The elevated antibody levels persisted for at least six months post-vaccination[1][2][6][8]. The Sendai virus platform is also being explored as a vector backbone for vaccines against other respiratory viruses such as RSV and hMPV[2].
- Other names
- Sendai virus vaccineSeV vaccineintranasal Sendai virus vaccine
02
Targets
Sendai virus fusion protein at the hemagglutinin-neuraminidase interfaceSA (Sialic acid)
Beyond the preview
Go deeper on Sendai virus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sendai virus vaccine.